Oxford Biomedica plc operates as a contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. The company focuses on the development and manufacturing of viral vectors, including lentivirus and adeno-associated virus (AAV), for pharmaceutical and biotechnology clients. Its services span from early-stage development to commercial production, supported by quality assurance and regulatory expertise. Oxford Biomedica has facilities in the UK, France, and the US, serving a global market with a growing demand for advanced therapeutic solutions.